CEO Sandy Macrae, PhD, told GEN Edge that Sangamo plans to dose a total of nine patients. The second patient is expected to be dosed by the middle of 2022. Dosing of patients occurs several months after patient enrollment, as prior to dosing each patient needs to undergo leukapheresis to collect their white blood cells, after which their Treg cells are isolated, genetically engineered, then cryopreserved . . .
The post Sangamo Advances Kidney Transplant Cell Therapy into the Clinic appeared first on GEN – Genetic Engineering and Biotechnology News.